Compare DUOT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | VYGR |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 203.6M |
| IPO Year | 2017 | 2015 |
| Metric | DUOT | VYGR |
|---|---|---|
| Price | $11.34 | $3.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $17.00 | $16.50 |
| AVG Volume (30 Days) | ★ 713.0K | 475.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,023,651.00 | $10,135,000.00 |
| Revenue This Year | $50.98 | $34.04 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 271.16 | N/A |
| 52 Week Low | $5.78 | $2.83 |
| 52 Week High | $15.28 | $5.55 |
| Indicator | DUOT | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 50.42 |
| Support Level | $7.52 | $3.29 |
| Resistance Level | $11.33 | $4.26 |
| Average True Range (ATR) | 1.29 | 0.19 |
| MACD | -0.23 | 0.04 |
| Stochastic Oscillator | 14.21 | 74.11 |
Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.